Compassionate Use of Hydroxychloroquine in Clinical Practice for Patients With Mild to Severe COVID-19 in a French University Hospital.
Olivier PaccoudFlorence TubachAmandine BaptisteAlexandre BleibtreuDavid HajageGentiane MonselGianpiero TebanoDavid BoutolleauElise KlementNagisa GodefroyRomain PalichOula ItaniAntoine FaiçalMarc-Antoine ValantinRoland TubianaSonia BurrelVincent CalvezEric CaumesAnne-Geneviève MarcelinValerie PourcherPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
In hospitalized adults with COVID-19, no significant reduction of the risk of unfavorable outcomes was observed with hydroxychloroquine in comparison to SOC. Unmeasured confounders may have persisted however, despite careful propensity-weighted analysis and the study might be underpowered. Ongoing controlled trials in patients with varying degrees of initial severity on a larger scale will help determine whether there is a place for hydroxychloroquine in the treatment of COVID-19. In hospitalized adults with COVID-19, no significant reduction of the risk of unfavorable outcomes was observed with hydroxychloroquine in comparison to SOC.